瑞美吉泮治疗眩晕相关前庭和耳蜗症状：一项真实世界回顾性研究
Rimegepant for vestibular and cochlear symptoms associated with vertigo in a real-world retrospective study.
文献信息
| PMID | 42824127 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Ziyu Zhai |
| 作者单位 | Department of Otolaryngology, Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. |
| 期刊 | iScience |
| SCI 分区 | Q1 |
| IF | 5 |
| 研究类型 | 临床研究 · 临床 |
| 所属专科 | 耳科 |
中文摘要
背景： 眩晕常与耳蜗症状同时出现，然而针对降钙素基因相关肽（CGRP）受体拮抗剂在听觉前庭疾病中的证据仍然有限。方法：我们回顾性评估了54名接受瑞美吉泮75 mg每日一次或隔日一次治疗8周的眩晕成人患者。结果：瑞美吉泮使用与每月眩晕和头痛天数、耳鸣严重程度及心理评估评分的降低相关，同时纯音平均听阈和耳闷胀感也有所改善。到第8周时，94.4%的患者每月眩晕天数至少减少50%，中位感知改善起效时间为6天。在探索性分析中，每日给药与隔日给药相比，每月眩晕天数的减少幅度更大。结论：这些发现提供了初步的真实世界证据，支持对CGRP靶向治疗用于眩晕相关前庭和耳蜗症状进行前瞻性对照评估。
英文摘要
Vertigo commonly co-occurs with cochlear symptoms, yet evidence for calcitonin gene-related peptide (CGRP) receptor antagonists across audiovestibular disorders remains limited. We retrospectively evaluated 54 adults with vertigo who received rimegepant 75 mg daily or every other day for 8 weeks. Rimegepant use was associated with reductions in monthly vertigo and headache days, tinnitus severity, and psychological assessment scores, as well as improvements in pure-tone average and aural fullness. By week 8, 94.4% of patients achieved at least a 50% reduction in monthly vertigo days, and the median perceived onset of improvement was 6 days. In exploratory analysis, daily dosing was associated with a greater reduction in monthly vertigo days than alternate-day dosing. These findings provide preliminary real-world evidence supporting prospective controlled evaluation of CGRP-targeted therapy for vertigo-associated vestibular and cochlear symptoms.